<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-05-14T12:12:27Z</responseDate><request verb="GetRecord" identifier="oai:riubu.ubu.es:10259/10192" metadataPrefix="mods">https://riubu.ubu.es/oai/request</request><GetRecord><record><header><identifier>oai:riubu.ubu.es:10259/10192</identifier><datestamp>2026-01-19T09:16:16Z</datestamp><setSpec>com_10259_3844</setSpec><setSpec>com_10259_5086</setSpec><setSpec>com_10259_2604</setSpec><setSpec>col_10259_3845</setSpec></header><metadata><mods:mods xmlns:mods="http://www.loc.gov/mods/v3" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:namePart>Sanz Villafruela, Juan</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Bermejo Casadesus, Cristina</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Zafon, Elisenda</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Martínez Alonso, Marta</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Durá, Gema</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Heras Vidaurre, Aránzazu</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Soriano Díaz, Iván</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Giussani, Angelo</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Ortí, Enrique .</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Tebar, Francesc</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Espino Ordóñez, Gustavo</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Massaguer Vall-Llovera, Anna</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAvailable encoding="iso8601">2025-02-10T09:20:47Z</mods:dateAvailable>
</mods:extension>
<mods:extension>
<mods:dateAccessioned encoding="iso8601">2025-02-10T09:20:47Z</mods:dateAccessioned>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2024-10</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="issn">0223-5234</mods:identifier>
<mods:identifier type="uri">http://hdl.handle.net/10259/10192</mods:identifier>
<mods:identifier type="doi">10.1016/j.ejmech.2024.116618</mods:identifier>
<mods:abstract>Ir(III) and Ru(II) polypyridyl complexes are promising photosensitizers (PSs) for photodynamic therapy (PDT)&#xd;
due to their outstanding photophysical properties. Herein, one series of cyclometallated Ir(III) complexes and&#xd;
two series of Ru(II) polypyridyl derivatives bearing three different thiazolyl-β-carboline N^N′ ligands have been&#xd;
synthesized, aiming to evaluate the impact of the different metal fragments ([Ir(C^N)2]&#xd;
+ or [Ru(N^N)2]&#xd;
2+) and&#xd;
N^N’ ligands on the photophysical and biological properties. All the compounds exhibit remarkable photo&#xd;
stability under blue-light irradiation and are emissive (605 &lt; λem &lt; 720 nm), with the Ru(II) derivatives dis&#xd;
playing higher photoluminescence quantum yields and longer excited state lifetimes. The Ir PSs display pKa&#xd;
values between 5.9 and 7.9, whereas their Ru counterparts are less acidic (pKa > 9.3). The presence of the&#xd;
deprotonated form in the Ir-PSs favours the generation of reactive oxygen species (ROS) since, according to&#xd;
theoretical calculations, it features a low-lying ligand-centered triplet excited state (T1 = 3&#xd;
LC) with a long&#xd;
lifetime. All compounds have demonstrated anticancer activity. Ir(III) complexes 1–3 exhibit the highest cyto&#xd;
toxicity in dark conditions, comparable to cisplatin. Their activity is notably enhanced by blue-light irradiation,&#xd;
resulting in nanomolar IC50 values and phototoxicity indexes (PIs) between 70 and 201 in different cancer cell&#xd;
lines. The Ir(III) PSs are also activated by green (with PI between 16 and 19.2) and red light in the case of&#xd;
complex 3 (PI = 8.5). Their antitumor efficacy is confirmed by clonogenic assays and using spheroid models. The&#xd;
Ir(III) complexes rapidly enter cells, accumulating in mitochondria and lysosomes. Upon photoactivation, they&#xd;
generate ROS, leading to mitochondrial dysfunction and lysosomal damage and ultimately cell apoptosis.&#xd;
Additionally, they inhibit cancer cell migration, a crucial step in metastasis. In contrast, Ru(II) complex 6 exhibits moderate mitochondrial activity. Overall, Ir(III) complexes 1–3 show potential for selective light-controlled cancer treatment, providing an alternative mechanism to chemotherapy and the ability to inhibit lethal cancer cell dissemination.</mods:abstract>
<mods:language>
<mods:languageTerm>eng</mods:languageTerm>
</mods:language>
<mods:accessCondition type="useAndReproduction">http://creativecommons.org/licenses/by/4.0/</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">info:eu-repo/semantics/openAccess</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">Atribución 4.0 Internacional</mods:accessCondition>
<mods:subject>
<mods:topic>Cancer</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Photodynamic therapy</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Cyclometalated complexes</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Mitochondria</mods:topic>
</mods:subject>
<mods:titleInfo>
<mods:title>Insights into the anticancer photodynamic activity of Ir(III) and Ru(II) polypyridyl complexes bearing β-carboline ligands</mods:title>
</mods:titleInfo>
<mods:genre>info:eu-repo/semantics/article</mods:genre>
</mods:mods></metadata></record></GetRecord></OAI-PMH>